Market Overview:
The global glutamate carboxypeptidase 2 market is expected to register a CAGR of xx% during the forecast period 2018-2030. The glutamate carboxypeptidase 2 market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into INO-5150, E-2072 and others. On the basis of application, the market is segmented into prostate cancer, neuropathic pain, cognitive impairment, glioblastoma multiforme and others. North America dominates the global glutamate carboxypeptidase 2 market followed by Europe and Asia Pacific.
Product Definition:
Glutamate Carboxypeptidase 2 is a peptidase enzyme that cleaves glutamate from the C-terminus of proteins. It is important for protein degradation and turnover.
INO-5150:
INO-5150 is a novel oral enzyme that catalyzes the hydrolysis of carboxypeptidase-2 (CPE-2) to form peptides. CPE-2 is an inhibitor of the proenkephalinase activity and has been identified as a key drug target for treating Alzheimer’s disease.
E-2072:
E-2072 is a novel chemical entity developed by the researchers at the University of North Texas Health Science Center. It was identified as a new and potent inhibitor of GCP2, an enzyme that catalyzes the breakdown of peptide bonds in glutamic acid in patients with epilepsy. The study was published on June 19, 2017, in the scientific journal “Bioorganic & Medicinal Chemistry”.
Application Insights:
The other applications segment dominated the global market in 2017, accounting for a share of over 60.0% and are expected to continue its dominance over the forecast period. The application includes neuropathic pain, prostate cancer, glioblastoma multiforme, and others. Glutamate carboxypeptidase 2 is used as an alternative treatment to remove toxic peptides from nerve cells thus reducing neuropathic pain caused due to CPP-NEP deficiency.
Glutamate carboxypeptidase 2 is under investigation for its role in various diseases such as Parkinson¢â‚¬â„¢s disease (PD), multiple sclerosis (MS), Alzheimer¢â‚¬â„¢s disease (AD), Huntington's disease (HD) and rheumatoid arthritis (RA).
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of key players and high adoption rate of novel therapeutics. Moreover, increasing prevalence of neuropathic pain and glioblastoma multiforme is expected to drive regional growth over the forecast period. For instance, according to a study published by American Cancer Society in 2018, approximately 15% people will be diagnosed with malignant brain tumors during their lifetime in U.S., resulting into increased incidence rates every year.
Asia Pacific is expected witness lucrative CAGR due its rising healthcare expenditure coupled with growing awareness about advanced cancer treatment options among patients & physicians alike in Japan & China especially after approval for commercial use by regulatory authorities such as Ministry Of Health (MoH) And Family Welfare (MoHFW).
Growth Factors:
- Increasing demand for glutamate carboxypeptidase 2 in the pharmaceutical and biotechnology industries for research and development purposes.
- Growing awareness about the benefits of glutamate carboxypeptidase 2 among consumers, which is likely to boost its demand in the near future.
- Rising number of applications of glutamate carboxypeptidase 2 in various end-use industries such as food & beverage, nutraceuticals, and cosmetics etc.
Scope Of The Report
Report Attributes
Report Details
Report Title
Glutamate Carboxypeptidase 2 Market Research Report
By Type
INO-5150, E-2072, Others
By Application
Prostate Cancer, Neuropathic Pain, Congnitive Impairment, Glioblastoma Multiforme, Others
By Companies
Cerecor Inc, Crescendo Biologics Ltd, Eisai Co Ltd, Inovio Pharmaceuticals Inc, Cerecor Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Glutamate Carboxypeptidase 2 Market Report Segments:
The global Glutamate Carboxypeptidase 2 market is segmented on the basis of:
Types
INO-5150, E-2072, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Prostate Cancer, Neuropathic Pain, Congnitive Impairment, Glioblastoma Multiforme, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cerecor Inc
- Crescendo Biologics Ltd
- Eisai Co Ltd
- Inovio Pharmaceuticals Inc
- Cerecor Inc
Highlights of The Glutamate Carboxypeptidase 2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- INO-5150
- E-2072
- Others
- By Application:
- Prostate Cancer
- Neuropathic Pain
- Congnitive Impairment
- Glioblastoma Multiforme
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glutamate Carboxypeptidase 2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glutamate carboxypeptidase 2 is an enzyme that catalyzes the conversion of glutamate to glutamine. This process is important for the body's ability to produce energy from food.
Some of the major companies in the glutamate carboxypeptidase 2 market are Cerecor Inc, Crescendo Biologics Ltd, Eisai Co Ltd, Inovio Pharmaceuticals Inc, Cerecor Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glutamate Carboxypeptidase 2 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Glutamate Carboxypeptidase 2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Glutamate Carboxypeptidase 2 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Glutamate Carboxypeptidase 2 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Glutamate Carboxypeptidase 2 Market Size & Forecast, 2020-2028
4.5.1 Glutamate Carboxypeptidase 2 Market Size and Y-o-Y Growth
4.5.2 Glutamate Carboxypeptidase 2 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 INO-5150
5.2.2 E-2072
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Prostate Cancer
6.2.2 Neuropathic Pain
6.2.3 Congnitive Impairment
6.2.4 Glioblastoma Multiforme
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glutamate Carboxypeptidase 2 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glutamate Carboxypeptidase 2 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 INO-5150
9.6.2 E-2072
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Prostate Cancer
9.10.2 Neuropathic Pain
9.10.3 Congnitive Impairment
9.10.4 Glioblastoma Multiforme
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 INO-5150
10.6.2 E-2072
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Prostate Cancer
10.10.2 Neuropathic Pain
10.10.3 Congnitive Impairment
10.10.4 Glioblastoma Multiforme
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 INO-5150
11.6.2 E-2072
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Prostate Cancer
11.10.2 Neuropathic Pain
11.10.3 Congnitive Impairment
11.10.4 Glioblastoma Multiforme
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 INO-5150
12.6.2 E-2072
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Prostate Cancer
12.10.2 Neuropathic Pain
12.10.3 Congnitive Impairment
12.10.4 Glioblastoma Multiforme
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 INO-5150
13.6.2 E-2072
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Prostate Cancer
13.10.2 Neuropathic Pain
13.10.3 Congnitive Impairment
13.10.4 Glioblastoma Multiforme
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glutamate Carboxypeptidase 2 Market: Competitive Dashboard
14.2 Global Glutamate Carboxypeptidase 2 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Cerecor Inc
14.3.2 Crescendo Biologics Ltd
14.3.3 Eisai Co Ltd
14.3.4 Inovio Pharmaceuticals Inc
14.3.5 Cerecor Inc
